AKR1C3 Enzyme Precursor Drug
OBI-3424 is a prodrug targeting AKR1C3-enzyme. In May 2017, the Company acquired this asset with the intention to continue research and development and to ultimately commercialize OBI-3424 in major global markets outside of Asia. An IND application is expected to be filed in the first quarter of 2018. The AKR1C3 enzyme is highly expressed in over 15 types of tumors, and is mainly involved in hormone synthesis and the elimination of toxins. Under AKR1C3 enzyme catalysis inside tumor cells, OBI-3424 will be transformed into an active anticancer cytotoxic agent. OBI-3424 is also the most advanced drug under research and development for this mechanism.